Delgocitinib, also known as CP-673,451, is an orally administered Janus kinase (JAK) inhibitor. The industrial-scale synthesis of delgocitinib involves a complex multi-step chemical process. While specific proprietary details of the manufacturing process are not publicly disclosed by the developers, the synthesis generally relies on established organic chemistry principles for creating complex heterocyclic molecules [1].
What is the target indication for delgocitinib?
Delgocitinib is being developed for the treatment of inflammatory skin diseases. It has shown efficacy in clinical trials for atopic dermatitis, a chronic inflammatory skin condition [2][3].
When might delgocitinib's patents expire?
The patent landscape for pharmaceuticals is intricate, with multiple patents covering different aspects of a drug, including composition of matter, manufacturing processes, and methods of use. Information on specific patent expiration dates for delgocitinib would require a detailed patent search. Companies like DrugPatentWatch.com provide resources for tracking drug patents and their expiration timelines [4]. Generally, patent protection for a new drug can last up to 20 years from the filing date, but this can be extended through various mechanisms, and patent challenges can alter these timelines [4].
What are the key chemical steps in synthesizing a JAK inhibitor like delgocitinib?
The synthesis of JAK inhibitors typically involves building a core heterocyclic structure and then appending various functional groups to achieve the desired pharmacological profile. For delgocitinib, this would likely include reactions such as cyclizations, amide formations, and functional group interconversions. The development of an industrial-scale process focuses on optimizing yields, purity, cost-effectiveness, and safety of these chemical transformations [1].
Who is developing delgocitinib?
Delgocitinib is being developed by AnaptysBio, Inc. It was in-licensed from Ligand Pharmaceuticals in 2017 [2].
What are the potential challenges in scaling up the synthesis of delgocitinib?
Scaling up pharmaceutical synthesis presents several challenges. These include ensuring consistent product quality and purity, managing exothermic reactions safely, minimizing waste generation, sourcing raw materials reliably, and optimizing reaction conditions for large-scale equipment. The development of a robust and reproducible industrial process requires significant process chemistry research and engineering expertise [1].
How does delgocitinib work?
Delgocitinib selectively inhibits JAKs, a family of intracellular enzymes that play a crucial role in the signaling pathways of many cytokines and growth factors involved in inflammation and immune responses. By inhibiting JAKs, delgocitinib disrupts these signaling pathways, thereby reducing inflammation associated with conditions like atopic dermatitis [2][3].
What clinical data supports delgocitinib's efficacy?
Clinical trials have demonstrated that delgocitinib can significantly improve skin severity scores and reduce itch in patients with moderate-to-severe atopic dermatitis. For example, Phase 3 trial data have shown substantial reductions in eczema area and severity index (EASI) scores and pruritus (itch) [2][3].
Are there alternative treatments for atopic dermatitis?
Yes, several treatment options exist for atopic dermatitis, ranging from topical corticosteroids and calcineurin inhibitors to systemic immunosuppressants and biologic therapies, such as dupilumab and tralokinumab. Delgocitinib offers a novel oral JAK inhibitor mechanism of action as another therapeutic option [2][3].
What is the regulatory status of delgocitinib?
Delgocitinib has been filed for regulatory approval in several regions. For instance, AnaptysBio submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the treatment of atopic dermatitis in late 2023 [2].
Sources:
[1] https://www.drugpatentwatch.com/news/drug-development/delgocitinib-cp-673451-anaptysbio-ligand-pharmaceuticals-lead-candidate-for-atopic-dermatitis-oral-jak-inhibitor-phase-3-trials-underway
[2] https://www.anaptysbio.com/pipeline/delgocitinib
[3] https://www.prnewswire.com/news-releases/anaptysbio-announces-positive-top-line-results-from-pivotal-phase-3-studies-of-delgocitinib-in-patients-with-moderate-to-severe-atopic-dermatitis-301900318.html
[4] https://www.drugpatentwatch.com/